-
Uncategorized2 months ago
Boehringer Ingelheim to expand its AI footprint in UK, in £150M investment
Boehringer Ingelheim to expand its AI footprint in UK, in £150M investment
-
Uncategorized2 months ago
Biotech has become a good news story. Let the sun shine
Doubling survival in pancreatic cancer, a long-fought rare disease approval, a massive IPO and ambitious biotech entrepreneurs have BioSpace Senior Editor Annalee Armstrong feeling upbeat about...
-
Uncategorized2 months ago
Lilly adds gene delivery technology to CAR T in up to $7B Kelonia deal
After entering the CAR T space in February, Eli Lilly is “jumping into in vivo CAR-T with both feet” with the acquisition of Kelonia Therapeutics and...
-
Uncategorized2 months ago
Agenus cancer cocktail records 0% response rate, missing midstage goal
Agenus cancer cocktail records 0% response rate, missing midstage goal
-
Uncategorized2 months ago
Novo’s late-stage sickle cell win piles pressure on competitors
Novo Nordisk’s etavopivat elicited a 27% drop in vaso-occlusive crises and 48.7% hemoglobin response after 24 weeks, creating “separation amongst PK class candidates,” Truist analysts said...
-
Uncategorized2 months ago
STAT+: Finally cracking KRAS as a druggable target
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hiya. Today, we see a...
-
Uncategorized2 months ago
Lilly to buy Kelonia for $3.25B upfront, underlining its in vivo CAR-T strategy
Eli Lilly is going big on in vivo CAR-T therapy. The company said Monday that it would buy Kelonia Therapeutics, which has a Phase 1 program...
-
Uncategorized2 months ago
AACR: Endeavoring to go global, Zai Lab offers reality check on China’s biotech ascent
Since its 2014 founding, Zai Lab has built its business by licensing drugs from Big Pharma. But in the last three years, the company has sought...
-
Uncategorized2 months agoSTAT+: Pharmalittle: We’re reading about Trump boosting psychedelic treatment, the future for weight-loss drugs, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and rewarding, because that oh-so-familiar routine of meetings, online calls,...
-
Uncategorized2 months agoDecoding Resistance to Targeted Therapy via New Cancer Models
ATCC and the Broad Institute report the development of engineered isogenic cancer models designed to replicate resistance to targeted therapies, beginning with osimertinib, the latest-generation epidermal...
STAT+: Up and down the ladder: The latest comings and goings
FDA imposes import alert on Indian plant after inspectors flag GMP failings
